Claim Missing Document
Check
Articles

Found 13 Documents
Search

Clinical Manifestations of the Gastrointestinal System in Patients with SARS-CoV-2 Infection Kharizmatika Kharizmatika; Judya Sukmana; Roostantia Indrawati; Christian Bambang Sulistio
MAHESA : Malahayati Health Student Journal Vol 4, No 10 (2024): Volume 4 Nomor 10 (2024)
Publisher : Universitas Malahayati

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33024/mahesa.v4i10.15845

Abstract

ABSTRACT SARS-CoV-2 infection was declared as a pandemic by the WHO since March 11, 2020, with confirmed cases increasing every year. SARS-CoV-2 is one of the varian of coronavirus that has a higher transmission rate, where it is transmitted through infected droplets. SARS-CoV-2 can manifest in the digestive tract. This descriptive study uses a literature study method. Diarrhea was a common symptom of gastrointestinal manifestations in COVID-19 patients. Apart from diarrhea, other symptoms are anorexia, nausea, vomiting and abdominal pain. Gender prevalence varies. The average age of patients exposed to COVID-19 was over 50 years with hypertension as the most common comorbidity. SARS-CoV-2 are associated with Gastrointestinal manifestations which binds to ACE2 on gastrointestinal epithelial cells. SARS-CoV-2 infection causes an imbalance in the gut microbiota that can trigger secondary infections and multiple organ disorders and affect the severity of COVID-19. Keywords: COVID-19, Gastrointestinal Symptoms, ACE2, Gut Microbiota, Gut-Lung Axis
Penatalaksanaan Pasien Penyakit Jantung Koroner Di RSPAL dr. Ramelan Surabaya ZULVINA, NADIFA FAULIZA; M. FATHUDDIN AL-ISLAMI; NABELLA CHOLIDATUN NIKMAH; NADHIFA NURIZZAH DHIYANISA; NADIFA SALMA SARI; ROOSTANTIA INDRAWATI; INTAN KOMALASARI
Hang Tuah Medical Journal Vol 22 No 2 (2025): Hang Tuah Medical Journal
Publisher : Universitas Hang Tuah

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30649/htmj.v22i2.503

Abstract

Background: World Health Organization (WHO) data shows that coronary heart disease is the highest mortality and morbidity throughout the world among other heart and vascular diseases, namely around 43%. The pharmacological therapy is evaluated based on the rationality of drug use including the right indication, the right drug, the right patient and the right dose. The aim of evaluating rational drug use is to ensure that patients receive treatment that suits their needs and at an affordable price. The rational use of drugs is important in the success of disease and improving the quality of health. Methode: The method in research uses an observational analytical method with a retrospective cross-sectional approach, with a purposive sampling technique. Data obtained from the patient's medical record status. The population in this study were all outpatients with a diagnosis of coronary heart disease in The Polyclinic Cardiology Department at RSPAL dr. Ramelan Surabaya period of January – March 2023. Result : The most patient characteristics based on range of age were in the 56 until 65 years old, namely 113 patients (33.43%). Characteristics of patients based on gender, the highest number of coronary heart medication users were men, 240 patients (71%). Characteristics of patients based on comorbidities (with comorbidities) were mostly with comorbidities, 296 patients (88%). The percentage of rational drugs of use includes the right indication (78.70%), the right drug (82.25%), the right dose (100%), and the right patient (99.11%). Conclusion: The rationale for using coronary heart medication in coronary heart patients in the outpatient installation at RSPAL dr. Ramelan Surabaya is 94.30% rational. Keywords: Coronary Heart Disease, Evaluation of Drug Use, Drug Evaluation, Outpatient.
Exploring Hope in Chia Seed-Derived Myricetin: In silico Study of Antimalarial and Anti-inflammatory Agent Against Plasmodium falciparum Neyza Farah Najmasari; Prawesty Diah Utami; Roostantia Indrawati; Herin Setianingsih
Indonesian Journal of Tropical and Infectious Disease Vol. 14 No. 2 (2026): Vol. 14 No. 2 (2026)
Publisher : Institute of Topical Disease Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/ijtid.v14i2.85261

Abstract

Artemisinin Combination Therapy (ACT) currently serves as the primary regimen for global malaria treatment. However, the widespread emergence of artemisinin resistance poses a critical threat that risks severely diminishing the therapeutic value of the existing regimens. This growing clinical challenge underscores an urgent need to identify antimalarial drug candidates with distinct mechanism of action. This computational study investigates myricetin, a flavonoid compound derived from chia seeds (Salvia hispanica L.), as a potential candidate with antimalarial and anti-inflammatory activity.  Myricetin was evaluated based on predicted pharmacokinetic behavior, toxicity risk, and drug-likeness, using artemisinin as a reference compound. Docking analysis was performed to examine predicted interactions between myricetin and Plasmodium falciparum enzymes (plasmepsin-II and falcipain-2), as well as inflammation-related targets (TNF-α and IL-10). ADME analysis outlined characteristics regarding absorption, distribution, metabolism, and excretion, while toxicity models indicated potential nephrotoxicity and respiratory toxicity. Predictions of myricetin interactions with plasmepsin-II and falcipain-2 proteins suggested favorable predicted binding to the active sites of the proteins with MolDock scores of -239.2 kJ/mol and -215 kJ/mol, respectively. Furthermore, predictions of myricetin interactions with TNF-α and IL-10 suggested possible relevance to inflammation-related pathways, although these computational findings cannot confirm cytokine regulation. Based on Lipinski and Ghose drug-likeness screening criteria, myricetin exhibited a drug-like profile generally comparable to that of artemisinin. Overall, myricetin represents a promising computational lead candidate for the development of antimalarial and anti-inflammatory drugs. However, further cell-based assays (in vitro), animal studies (in vivo), pharmacokinetic evaluations, and toxicity confirmation are required before drawing conclusions regarding efficacy, safety, or the effects of oral administration.